Swedish Cancer Detection Company Elypta Joins European Innovation Council Scaling Club – could it Become a Unicorn?
October 30, 2024 Solna, Sweden. Swedish life science company Elypta is delighted to announce its inclusion in the European Innovation Council’s (EIC) Scaling Club.
The EIC Scaling Club is one of the world’s most respected accelerators and features more than 120 of the EU’s most innovative deep tech scaleups. Tackling issues spanning health, green energy and material science, the EIC Scaling Club aims to grow its member companies’ revenues by 40% per year. Its mission is for 20% of its members to become unicorns – privately-owned companies worth over US$1bn.
Elypta’s participation will accelerate the development of its cutting-edge diagnostics platform, which could provide clinicians with the tools necessary to redefine cancer diagnostics.
At the core of Elypta’s MIRAM® platform are human glycosaminoglycans (GAGs) - these are crucial components of tumor microenvironments, and several recent studies have demonstrated their potential as cancer biomarkers. Elypta believes that the GAGome – the makeup of GAGs found in the body – is often altered years before cancer develops and, through effective testing, patients at higher risk of developing cancer can be stratified from general populations for more frequent testing.
Speaking about the company’s inclusion in the EIC Scaling Club, Elypta CEO, Karl Bergman, said: “The whole team at Elypta is delighted to be part of the club. With multiple clinical studies in the works – including EU Horizon 2020 funded AURORAX-0087A , which aims to support registration of the first ever urine test for detection of recurring kidney cancer – Elypta is well positioned to scale significantly. I look forward to the coming year, and all the work we will do with the club.”
For more information, please contact:
Karl Bergman, CEO, info@elypta.com
Barnaby Pickering, Associate, Barnaby@rhacomms.eu
About Elypta
Elypta is a Swedish cancer detection company focused on reducing cancer mortality by enabling earlier detection and closer monitoring. The metabolism-based liquid biopsy platform measures a novel panel of glycosaminoglycan biomarkers (GAGome) and algorithms trained to detect cancer-specific signatures. Elypta is advancing a broad study program across different cancers with the leading indications being early detection of recurrence in renal cell carcinoma and multi-cancer early detection. www.elypta.com
About EIC Scaling Club
The EIC Scaling Club is a curated community where 120+ European deep tech scale-ups with the potential to build world-class businesses and solve major global challenges come together with investors, corporate innovators, and other industry stakeholders to spur growth.
The deep-tech companies are carefully selected from a pool of high-growth scale-ups that have benefitted from EIC financial schemes, other European and national innovation programs, and beyond.
The EIC Scaling Club is an EIC-funded initiative run in partnership by Tech Tour, Bpifrance (EuroQuity), Hello Tomorrow, Tech.eu (Webrazzi), EurA and IESE Business School.
